Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.

Melissa JohnsonAnthony El-KhoueiryNavid HafezNehal LakhaniHirva MamdaniJordi RodonRachel E Sanborn Javier García Corbacho Valentina BoniMark StrohAlison L HannahSong WangHenry CastroAlexander Spira

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The Probody therapeutic platform enables targeting CD71, a previously undruggable ADC target, at tolerable doses associated with clinical activity.See related commentary by Oberoi and Garralda, p. 4459.

Keyphrases

endothelial cells
high throughput
cancer therapy
magnetic resonance imaging
pluripotent stem cells
drug delivery
drug induced